Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 14,17€(+814,19%). Der Median liegt bei 12,15€(+683,87%).
Kaufen | 10 |
Halten | 2 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -4 / 13 |
News
Cabaletta Bio Announces Pricing of Public Offering of Securities
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 10,800,000 shares of its common stock and accompanying warrants to purchase an aggregate of 10,800,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.00001 per pre-funded warrant. Cabaletta also granted the underwriters a 30-day option to purchase up to an additional 15,000,000 shares of common stock and/or warrants at the public offering price, less underwriting discounts and commissions. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $2.50 per share, is immediately exercisable from the date of issuance and will expire fifteen months from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $2.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $1.99999.» Mehr auf globenewswire.com
Cabaletta Bio: Sector Headwinds And Funding Issues
Cabaletta Bio's CAR T-cell therapy shows durable efficacy in autoimmune diseases, with manageable side effects and promising early clinical data updates. The company plans a BLA submission for myositis in 2027, supported by FDA's RMAT designation and a focused clinical trial strategy. Financial risk is significant: current cash plus a new offering extends runway only modestly, likely insufficient to reach commercialization without further dilution.» Mehr auf seekingalpha.com
Cabaletta Bio Announces Proposed Public Offering of Securities
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). Cabaletta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and warrants offered in the public offering. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by Cabaletta.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −33,22 Mio | 43,16% |
EBITDA | −34,33 Mio | 34,04% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 76,17 Mio€ |
Anzahl Aktien | 50,74 Mio |
52 Wochen-Hoch/Tief | 8,03€ - 0,86€ |
Dividenden | Nein |
Beta | 2,79 |
KGV (PE Ratio) | −0,68 |
KGWV (PEG Ratio) | 0,07 |
KBV (PB Ratio) | 0,70 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Cabaletta Bio, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase, das sich auf die Entdeckung und Entwicklung von T-Zell-Therapien für Patienten mit B-Zell-vermittelten Autoimmunkrankheiten konzentriert. Die firmeneigene Technologie nutzt chimäre Autoantikörper-Rezeptor (CAAR)-T-Zellen, die selektiv B-Zellen binden und eliminieren sollen, die krankheitsverursachende Autoantikörper oder pathogene B-Zellen produzieren. Der führende Produktkandidat des Unternehmens ist DSG3-CAART, der sich in der klinischen Phase I für die Behandlung von Pemphigus vulgaris, einer autoimmunen Hautkrankheit mit Blasenbildung, und von Hämophilie A mit Faktor-VIII-Aloantikörpern befindet. Die Produktkandidaten-Pipeline umfasst auch MuSK-CAART, ein Produkt im präklinischen Stadium zur Behandlung einer Untergruppe von Patienten mit Myasthenia gravis; FVIII-CAART, ein Produkt im Forschungsstadium zur Behandlung einer Untergruppe von Patienten mit Hämophilie A; und DSG3/1-CAART, ein Produkt im Forschungsstadium zur Behandlung von mukokutanem Pemphigus vulgaris. Es besteht eine Zusammenarbeit mit der University of Pennsylvania und eine Forschungsvereinbarung mit The Regents of the University of California. Das Unternehmen war früher als Tycho Therapeutics, Inc. bekannt und änderte im August 2018 seinen Namen in Cabaletta Bio, Inc. Cabaletta Bio, Inc. wurde im Jahr 2017 gegründet und hat seinen Hauptsitz in Philadelphia, Pennsylvania.
Name | CABALETTA BIO DL -,00001 |
CEO | Dr. Steven A. Nichtberger M.D. |
Sitz | Philadelphia, pa USA |
Website | |
Industrie | Nahrungsmittel |
Börsengang | |
Mitarbeiter | 161 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | CABA |
Assets entdecken
Shareholder von CABALETTA BIO DL -,00001 investieren auch in folgende Assets